We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

MINDRAY In-Vitro Diagnostics

  Gold Mindray offers a range of chemistry and hematology analyzers, designed to meet the needs of smaller labs as a main in... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Mindray Analyzers Help Detect Hematological Parameters to Support COVID-19 Diagnosis and Prognosis

By LabMedica International staff writers
Posted on 19 Apr 2021
Print article
Image: Mindray Analyzers Help Detect Hematological Parameters to Support COVID-19 Diagnosis and Prognosis (Photo courtesy of Mindray)
Image: Mindray Analyzers Help Detect Hematological Parameters to Support COVID-19 Diagnosis and Prognosis (Photo courtesy of Mindray)
Mindray (Shenzhen, China) hematology analyzers are using advanced technologies to detect inflammatory parameters, such as white blood cell count (WBC), neutrophil count, neutrophil-to-lymphocyte ratio (NLR) and red blood cells (RBC) that can support COVID-19 diagnosis and prognosis.

Identifying COVID-19 patients at highest risk for severe disease is important. In order to facilitate early intervention and to manage local hospital resources to mitigate the critical care crises, research is being conducted in routine, low-cost, and suggestive parameters to assist with COVID-19 prognosis and the identification of severe cases. Studies comparing hematological results from good and poor outcome groups of COVID-19 patients have revealed that the best single parameter for predicting the prognosis of severe patients is RDW-SD. Additionally, combined parameters Lym# & RDW-CV as well as Lym# & RDW-SD are better for predicting the prognosis of severe COVID-19. Researchers have also found that HGB is lower in the severe group than in the moderate group. New joint parameters Lym% and HGB have the best sensitivity and specificity. Hence, Lym% and HGB can be used as indicators of disease prognosis.

With advanced technologies, the newly combined hematological parameters, such as Lym% & RDW-SD, Lym# & HGB and NLR & RDW-SD, have been found as supportive predictors during COVID-19 prognostics. More and more covariates can be studied and developed on the Mindray BC-6000 series analyzers. Especially on BC-6800Plus, the RET channel can detect the number, size, and hemoglobin concentration of RBCs and RETs highly sensitive laser scattering technology. Thus, it is recommended to start using self-defined parameters for COVID-19 prognosis now.


Gold Supplier
SARS-CoV-2 Master Assay
Allplex SARS-CoV-2 Master Assay
New
Digital Test Reader
ellume•lab
New
PCR System
Biomark HD
New
Influenza A & B Viruse Antigen Test
Influ A+B K-SeT

Print article

Channels

Molecular Diagnostics

view channel
Image: The Lumipulse G β-amyloid 1-40 assay kit (Photo courtesy Fujirebio)

APOE Gene Influences Alzheimer's Symptoms, Biomarkers in Down Syndrome

Individuals with Down syndrome (DS) constitute a population at ultrahigh risk of developing Alzheimer disease (AD) because of trisomy of chromosome 21, which harbors the amyloid precursor protein (APP) gene.... Read more

Industry

view channel
Illustration

ELITechGroup Acquires Freezing Point Osmometry Provider GONOTEC

ELITechGroup (Puteaux, France) has acquired GONOTEC (Berlin, Germany), thus uniting two osmometry market leaders. The acquisition will also provides the industry with a full range of osmometry solutions... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.